Documents

Displaying 21 - 40 of 76 results
 
Collapse Filters
 
Expand Filters         +
June 1, 2018

The Drug Situation in New Jersey (2018)

The Drug Enforcement Administration (DEA) New Jersey Division’s Intelligence Program conducted a bi-annual assessment of the drug threats occurring within the State of New Jersey between January and June 2017. This report highlights the strategic and significant findings regarding the illicit drug trends in the New Jersey Division’s (NJD) area of responsibility (AOR). Unless otherwise noted, data and findings are from DEA reporting. 

May 1, 2018

2018 Fentanyl Remains the Most Significant Synthetic Opioid Threat in US

Fentanyl is the most prevalent and the most significant synthetic opioida threat to the United States and will very likely remain the most prevalent synthetic opioid threat in the near term. The fentanyl threat remains most severe in the white powder heroin user market in the Midwest and Northeast United States, and fentanyl availability continues to be primarily by itself or with heroin. Fentanyl mixtures with non-opioid substances are a cause for public health concern due to the high potential for large numbers of fatal overdoses in short periods of time; however, there is no evidence that transnational criminal organizations (TCO) are trafficking strategic quantities of fentanyl already mixed with non-opioid drugs. Fentanyl’s popularity is unlikely to be challenged in the near term, but traffickers will likely continue to produce new fentanyl-related substances and other novel opioids. 

April 1, 2018

Synthetic Cathinone Sold as Crack Cocaine in Baltimore

In June and July 2017, law enforcement authorities made multiple undercover purchases of crack cocaine from one dealer in Baltimore, MD. In September 2017, official laboratory results indicated that two of these purchases tested as N-ethylpentylone Hydrochloride, a synthetic cathinone (“bath salts”) derivative classified as a Schedule I Controlled Substance Analogue.

April 1, 2018

DEA Data Indicates Cocaine is the Number One Seized Drug in South Carolina

As of October 2017, a review of Drug Enforcement Administration (DEA) National Forensic Laboratory Information System (NFLIS) data show that cocaine submissions indicate it is the number one seized substance by incident by law enforcement officials in South Carolina. The number of submissions has fluctuated with a high of 4,764 (in 2010) and a low of 3,492 (in 2012). The percent of cocaine submissions has declined every year since 2011 when compared to all South Carolina submissions. 

March 30, 2018

Chapter 79: Security

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 78: Hazardous Waste and Chemical Storage

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 77: Safety

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 76: Laboratory Special Studies

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 75: Laboratory Financial and Resource Management

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 74: Managing Laboratory Stockpiles and Special Programs

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 73: Managing Laboratory Evidence

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 72: Staffing, Training, and Personnel Actions

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 71: Quality Assurance

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 70: Laboratory Operations

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Analysis of Drugs Manual

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

February 1, 2018

Cocaine/Fentanyl Combination in Pennsylvania

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) conducted an assessment of laboratory-analyzed drug seizures. Some seized cocaine exhibits were found to contain cocaine and fentanyl, as well as a combined cocaine and fentanyl presence in overdose death toxicology reporting. This analysis was conducted in response to reported increases in the co-occurrence of cocaine and fentanyl in other regions and subsequent inquiries regarding trends in Pennsylvania. 

February 1, 2018

Drug Presence in Pennsylvania 1999-2016

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) conducted a review of laboratory-analyzed drug seizures for the Commonwealth of Pennsylvania. The resulting analysis of this data formed the basis for estimating the level of drug presence in Pennsylvania and highlighted trends in drug availability between 1999 and 2016. 

February 1, 2018

Heroin Cocktail: An Analysis of Pennsylvania Laboratory Drug Seizure Data

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) Intelligence Program maintains situational awareness of drug availability, abuse, trafficking patterns, adulterants, concealment methods, etc., through analysis of law enforcement and public health information and data, as well as law enforcement source information. 

February 1, 2018

Deadly Contaminated Cocaine Widespread in Florida (2018)

A review of cocaine exhibits acquired by law enforcement authorities during operations across Florida and analyzed by forensic laboratories during the period from 2016 to 2017 revealed the widespread adulteration of cocaine with fentanyl and fentanyl-related substances. Fentanyl, a Schedule II opioid analgesic approximately 50 times more potent than heroin and 100 times more potent than morphine, carries a high risk of overdose and can be lethal at the 2-milligram range. Forensic chemists discovered fentanyl and fentanyl-related substances including acetyl fentanyl, carfentanil, Furanylfentanyl, and p-fluoroisobutyryl fentanyl in over 180 cocaine exhibits. Carfentanil, a synthetic opioid that is approximately 10,000 times more potent than morphine, was the most prevalent of the fentanyl-related substances found in Florida’s cocaine seizures. 

January 11, 2018

2017 Domestic Methamphetamine Threat Assessment Key Findings

The Domestic Methamphetamine Threat Assessment provides a comprehensive strategic assessment of the threat posed to the United States by the trafficking and use of methamphetamine. 

This report combines federal, state, and local law enforcement reporting; public health data; news reports; and intelligence from other government agencies to assess the methamphetamine threat to the United States. 

Methamphetamine is a Schedule II stimulant under the Controlled Substances Act (CSA). Methamphetamine is a synthetically-produced central nervous system stimulant that metabolizes slowly and has long-lasting effects. 

DEA US Badge
United States Drug Enforcement Administration DEA.gov is an official site of the U.S. Department of Justice